{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AP1903", "query": { "intervention": "AP1903" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AP1903&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T15:49:38.762Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03056339", "title": "Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-Lymphoid Malignancies", "Acute Lymphocytic Leukemia", "Chronic Lymphocytic Leukemia", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "iC9/CAR.19/IL15-Transduced CB-NK Cells", "type": "BIOLOGICAL" }, { "name": "AP1903", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "7 Years to 80 Years" }, "enrollment_count": 49, "start_date": "2017-06-21", "completion_date": "2023-03-06", "has_results": true, "last_update_posted_date": "2024-03-25", "last_synced_at": "2026-09-02T15:49:38.762Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03056339" }, { "nct_id": "NCT03016377", "title": "Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Immune System Diseases", "Immunoproliferative Disorders" ], "interventions": [ { "name": "iC9-CAR19 cells", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "3 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2012-03-22", "completion_date": "2037-09-12", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-09-02T15:49:38.762Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03016377" }, { "nct_id": "NCT07509008", "title": "Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer, Metastatic" ], "interventions": [ { "name": "TGFBR2 KO CAR27/IL-15 NK cells", "type": "DRUG" }, { "name": "Rimiducid (AP1903)", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-09-01", "completion_date": "2030-07-01", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-02T15:49:38.762Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07509008" }, { "nct_id": "NCT03301168", "title": "Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Leukemia, Acute Myeloid (AML), Child", "Lymphoma, Non-Hodgkin", "Myelodysplastic Syndromes", "Primary Immune Deficiency Disorder", "Osteopetrosis", "Cytopenia", "Hemoglobinopathy in Children", "Anemia, Aplastic" ], "interventions": [ { "name": "BPX-501 T cells", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bellicum Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "26 Years", "sex": "ALL", "summary": "1 Month to 26 Years" }, "enrollment_count": 120, "start_date": "2014-04", "completion_date": "2034-05", "has_results": false, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-09-02T15:49:38.762Z", "location_count": 10, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03301168" }, { "nct_id": "NCT07553390", "title": "Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan (T-DXd)", "type": "DRUG" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-10-01", "completion_date": "2038-03-30", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-02T15:49:38.762Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07553390" }, { "nct_id": "NCT03721068", "title": "Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Osteosarcoma" ], "interventions": [ { "name": "iC9.GD2.CAR.IL-15 T-cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": null, "sex": "ALL", "summary": "18 Months and older" }, "enrollment_count": 18, "start_date": "2019-02-19", "completion_date": "2044-06-19", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-02T15:49:38.762Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Chapel Hill, North Carolina", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03721068" }, { "nct_id": "NCT07164469", "title": "Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Large B-cell Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "CD70.CAR NK Cells", "type": "DRUG" }, { "name": "Rimiducid (AP1903)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 100, "start_date": "2026-12-28", "completion_date": "2033-09-30", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-02T15:49:38.762Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07164469" }, { "nct_id": "NCT02744287", "title": "Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Metastatic Prostate Cancer" ], "interventions": [ { "name": "BPX-601", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2016-11-30", "completion_date": "2023-03-14", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-09-02T15:49:38.762Z", "location_count": 13, "location_summary": "Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 9 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02744287" }, { "nct_id": "NCT03958656", "title": "T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloma-Multiple", "Myeloma, Plasma-Cell" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rimiducid", "type": "DRUG" }, { "name": "Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "73 Years", "sex": "ALL", "summary": "18 Years to 73 Years" }, "enrollment_count": 13, "start_date": "2019-06-13", "completion_date": "2021-01-19", "has_results": true, "last_update_posted_date": "2021-09-09", "last_synced_at": "2026-09-02T15:49:38.762Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03958656" }, { "nct_id": "NCT02231710", "title": "Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Immune Deficiency Disorders", "Hemophagocytic Lymphohistiocytosis", "Inherited Bone Marrow Failure Syndrome", "Hemoglobinopathies", "Metabolic Disorders" ], "interventions": [ { "name": "BPX-501 and Rimiducid", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bellicum Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Months", "maximum_age": "55 Years", "sex": "ALL", "summary": "4 Months to 55 Years" }, "enrollment_count": 1, "start_date": "2015-02", "completion_date": "2018-01", "has_results": true, "last_update_posted_date": "2024-03-25", "last_synced_at": "2026-09-02T15:49:38.762Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02231710" } ] }